» Articles » PMID: 6958215

Lack of in Vivo and in Vitro Bactericidal Activity of N-formimidoyl Thienamycin Against Enterococci

Overview
Specialty Pharmacology
Date 1982 Sep 1
PMID 6958215
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The minimal bactericidal concentrations of N-formimidoyl thienamycin (N-f-thienamycin) against 21 strains of enterococci isolated from patients with infective endocarditis were determined by macro- and microdilution methods. By a macrodilution technique with the minimal bactericidal concentration defined as greater than or equal to 99.9% killing of an initial inoculum, all 21 strains of enterococci were found to have minimal bactericidal concentration/minimal inhibitory concentration ratios of greater than or equal to 32. The mean minimal inhibitory concentration was 1.5 micrograms/ml (range, 0.5 to 4 micrograms/ml), and the minimal bactericidal concentration was greater than or equal to 128 micrograms/ml. The disparity between the results of our study and those published elsewhere, which reported that N-f-thienamycin is bactericidal in vitro against enterococci, may represent the relative insensitivity of the microdilution method in determining greater than or equal to 99.9% killing. The lack of in vitro bactericidal activity of N-f-thienamycin against enterococci was confirmed in vivo in the rabbit model of experimental endocarditis. N-f-Thienamycin was no more effective than penicillin alone in the treatment of experimental enterococcal endocarditis and was less effective than the combination of penicillin and gentamicin. The results indicate that N-f-thienamycin should not be used alone in the treatment of enterococcal endocarditis.

Citing Articles

Current perspectives on glycopeptide resistance.

Woodford N, Johnson A, Morrison D, Speller D Clin Microbiol Rev. 1995; 8(4):585-615.

PMID: 8665471 PMC: 172877. DOI: 10.1128/CMR.8.4.585.


Synergy of imipenem or penicillin G and aminoglycosides against enterococci isolated from patients with infective endocarditis.

Indrelie J, Wilson W, Matsumoto J, GERACI J, Washington 2nd J Antimicrob Agents Chemother. 1984; 26(6):909-12.

PMID: 6596907 PMC: 180048. DOI: 10.1128/AAC.26.6.909.


Imipenem/cilastatin.

Barza M Eur J Clin Microbiol. 1984; 3(5):453-5.

PMID: 6594233 DOI: 10.1007/BF02017374.


Synergistic effect of N-formimidoyl thienamycin with gentamicin and amikacin against Streptococcus faecalis.

Gombert M, Berkowitz L, Cummings M Antimicrob Agents Chemother. 1983; 23(2):245-7.

PMID: 6404218 PMC: 186030. DOI: 10.1128/AAC.23.2.245.


In vitro activity of imipenem--a review.

Braveny I Eur J Clin Microbiol. 1984; 3(5):456-62.

PMID: 6389125 DOI: 10.1007/BF02017375.


References
1.
Garrison P, FREEDMAN L . Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J Biol Med. 1970; 42(6):394-410. PMC: 2591670. View

2.
Kahan J, KAHAN F, Goegelman R, Currie S, Jackson M, Stapley E . Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo). 1979; 32(1):1-12. DOI: 10.7164/antibiotics.32.1. View

3.
Barry A, Lasner R . In-vitro methods for determining minimal lethal concentrations of antimicrobial agents. Am J Clin Pathol. 1979; 71(1):88-92. DOI: 10.1093/ajcp/71.1.88. View

4.
KROPP H, Sundelof J, Kahan J, KAHAN F, Birnbaum J . MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother. 1980; 17(6):993-1000. PMC: 283917. DOI: 10.1128/AAC.17.6.993. View

5.
Horadam V, Smilack J, Montgomery C, Werringloer J . In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin. Antimicrob Agents Chemother. 1980; 18(4):557-61. PMC: 284048. DOI: 10.1128/AAC.18.4.557. View